Meridian Bioscience (NASDAQ:VIVO) is scheduled to announce its earnings results before the market opens on Thursday, April 26th. Analysts expect the company to announce earnings of $0.20 per share for the quarter. Meridian Bioscience has set its FY18 guidance at $0.65-0.68 EPS.
Meridian Bioscience (NASDAQ:VIVO) last posted its earnings results on Thursday, January 25th. The company reported $0.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.01. Meridian Bioscience had a return on equity of 17.00% and a net margin of 10.46%. The firm had revenue of $52.30 million during the quarter, compared to analyst estimates of $49.00 million. During the same period in the previous year, the company earned $0.15 EPS. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. On average, analysts expect Meridian Bioscience to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
VIVO opened at $14.80 on Thursday. Meridian Bioscience has a twelve month low of $13.23 and a twelve month high of $16.45. The company has a debt-to-equity ratio of 0.28, a current ratio of 5.82 and a quick ratio of 3.96. The company has a market capitalization of $621.92, a P/E ratio of 22.09 and a beta of 0.96.
TRADEMARK VIOLATION WARNING: “Meridian Bioscience (VIVO) to Release Quarterly Earnings on Thursday” was first published by Week Herald and is the property of of Week Herald. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://weekherald.com/2018/04/19/meridian-bioscience-vivo-to-release-quarterly-earnings-on-thursday.html.
About Meridian Bioscience
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.